Allergan Aesthetics Showcases Commitment to Individuality, Innovation, and Integrity at IMCAS World Congress 2024

-- Expert-led symposium will explore key emerging themes in aesthetics, supported by injection session live from Allergan Aesthetics Center of Excellence in Italy --

-- New clinical data will be presented to support evolving Allergan Aesthetics portfolio --

-- 2024 marks 10 years of Allergan Medical Institute (AMI) and a decade of commitment to science and advanced education --

IRVINE, Calif., Jan. 25, 2024 /PRNewswire/ -- Allergan Aesthetics, the industry leader in aesthetics globally, continues to bring best-in-class programming highlighting Individuality, Innovation, and Integrity at the International Master Course on Aging Science (IMCAS) World Congress 2024 in Paris from February 1-3, 2024. Events include an Allergan Medical Institute (AMI) symposium, live injection session, Meet the Expert presentations, and an interactive exhibition booth that aesthetics practitioners can explore.

The congress activities are underpinned by the theme 'True Originals', highlighting the profound significance and influence originality plays in aesthetics. Allergan Aesthetics defines originality through three primary pillars:

• Individuality: Supporting practitioners to deliver a personalized aesthetic experience through consultation and superior technique, using a diverse aesthetics portfolio backed by science and data^1-2
• Innovation: Anticipating and serving the aesthetics needs of patients and providers to create new aesthetic categories and drive excellence in patient outcomes
• Integrity: Shaping the future of aesthetics through thoughtful patient engagement, the highest of ethical standards through training and collaboration maintaining high ethical values, advanced education, and meaningful partnerships.

IMCAS 2024 AMI Symposium

Ten years ago, Allergan Aesthetics united its long-standing training and educational programs to launch Allergan Medical Institute (AMI). 2024 marks a decade of advancing excellence in clinical practice while empowering confidence and elevating the craft of medical aesthetics around the world.

The AMI hosted symposium 'True Originals: Innovation to Empower Individuality' will spotlight what individuality means for the industry, and the impact of delivering individualized aesthetic results through real world examples straight from the experts. The session will conclude with a live injection session performed from the Allergan Center of Excellence in Italy.

Beyond the Symposium

La Tribune 2024:
On Friday February 2, 2004 Micah Bregman, VP Global Strategy and Pipeline, Allergan Aesthetics, will represent Allergan Aesthetics at La Tribune 2024. Taking place during the second session of the day, 4:00 PM – 6:00 PM CET in Amphi Havane, level 3.

New Clinical Data in Posters:

Meet the Experts:
Allergan Aesthetics will host a series of Meet the Experts sessions on the booth throughout the conference featuring: 

Aesthetic-Ethics:

IMCAS 2024 marks the preview of the Moving the Needle on Ethics book – a compilation of thought-provoking pieces on ethical topics associated with aesthetics, written by aesthetics practitioners from around the world and intended to continue the conversation on ethics in aesthetics.

Allergan Aesthetics Booth
The booth (E130, Level 1) will be a discovery hub for exploring Individuality, Innovation and Integrity in aesthetics and what it means to be truly original. 

About Allergan Aesthetics

At Allergan Aesthetics, an AbbVie (NYSE: ABBV) company, we develop, manufacture, and market a portfolio of leading aesthetics brands and products. Our aesthetics portfolio includes facial injectables, body contouring, plastics, skin care, and more. Our goal is to consistently provide our customers with innovation, education, exceptional service, and a commitment to excellence, all with a personal touch. For more information, visit www.allerganaesthetics.com 

About AbbVie

AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas – immunology, oncology, neuroscience, and eye care – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on LinkedIn, Facebook, Instagram, X (formerly Twitter), and YouTube.

Forward-Looking Statements

Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "anticipate," "project" and similar expressions and uses of future or conditional verbs, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. Such risks and uncertainties include, but are not limited to, challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, and changes to laws and regulations applicable to our industry. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie's operations is set forth in Item 1A, "Risk Factors," of AbbVie's 2022 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its subsequent Quarterly Reports on Form 10-Q. AbbVie undertakes no obligation, and specifically declines, to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.

References:

1. Allergan Aesthetics. Data on File. HArmonyCa™ Lidocaine. Clinical Study Report. July 2022. REF-99624.
2. Ogilvie, et al. J Cosmet Dermatol Surg, 2020: 1065 -1070

SOURCE AbbVie